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introDUCtion
Volumetric MRI sequences have improved greatly over 
the years but continue to be reserved for surgical and 
radiotherapy planning purposes and clinical trials, rarely 
forming part of routine contrast-enhanced studies of the 
brain.1 The authors would like to highlight the value of 
these sequences in routine neuro-oncological clinical 
practice in both baseline (diagnostic) and surveillance 
imaging, especially with regard to brain metastases and 
meningioma. The NICE guidelines for brain tumours in 
adults were published in July 20182 and recommend both 
pre- and post-contrast volumetric imaging as part of the 
standard structural imaging protocol for glioma, menin-
gioma and brain metastases. A more detailed protocol 
on specific sequences and technicalities of sequence 
acquisition has been published by the British Society for 
Neuroradiologists and this also recommends volumetric 
imaging sequences for glioma.3 Although these recom-
mendations exist, routine volumetric image acquisition 
in brain imaging has yet to find widespread adoption into 
clinical practice.
aDvantageS
There are several advantages of performing volumetric 
imaging at baseline. First, it may negate the need for an 
additional MRI study to obtain the volumetric sequences 
necessary for either surgical or radiotherapy planning 
thereby saving the patient from a repeated, unneces-
sary second dose of gadolinium contrast medium,4 and 
by reducing duplicate imaging which would be a cost 
saving for the NHS. Second, the inclusion of volumetric 
sequences in surveillance imaging protocols would allow 
the application of co-registration techniques, which have 
been shown to increase sensitivity in identifying patho-
logical changes.5 Co-registration techniques are readily 
available on most picture archiving and communication 
system systems. Furthermore, it “future proofs” any scans 
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aBStraCt
The acquisition of volumetric post-contrast MRI has clear advantages in the interpretation of neuro-oncology studies 
but has yet to find its way into routine clinical practice beyond planning scans for surgery and radiotherapy. This 
commentary briefly highlights the benefits of these techniques whilst dispelling some of the perceived disadvantages.
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at a later stage including quantitative volumetric assessment6,7 
or “radiomic” approaches utilising textural analysis.8 Volu-
metric measures also detect tumour growth more accurately 
(Figure  1) and are increasingly being utilized in drug devel-
opment trials.9 Furthermore, the use of radiosurgery for brain 
metastases has increased, in part due to the increased survival 
seen with new cancer therapies including immunotherapy. 
Volumetric imaging permits earlier detection of metastases, 
making the best use of modern radiosurgery platforms capable 
of treating multiple targets prior to clinical deterioration.10
There is evidence suggesting quantitative volumetric measure-
ments can provide additional prognostic information with 
regard to glioma. In low-grade glioma, changes in volume 
growth rate on T2 and FLAIR sequences can predict early 
malignant dedifferentiation11 and have shown better predic-
tion of malignant transformation compared to baseline 
volumetric measurement, relative cerebral blood volume 
(perfusion imaging) and measurements of apparent diffusion 
co-efficient (diffusion imaging).12 Following surgical treat-
ment for glioblastoma, a recent study has suggested that it is 
the actual volume of the tumour residuum rather than extent 
of resection, which has a greater effect on patient prognosis.13 
Interestingly, a comparison of two-dimensional RANO 
(response assessment in neuro-oncology) criteria and volu-
metric measurements in the first 12 weeks of bevacizumab 
treatment for glioblastoma multiforme (GBM) did not demon-
strate an advantage to performing a quantitative volumetric 
measurement over the more simple two-dimensional RANO 
measures,14 although not acknowledged by the authors, the 
acquisition of a volumetric sequence would ensure more reli-
able comparison with preceding studies via co-registration 
techniques to improve the accuracy of the two-dimensional 
measures. The routine incorporation of volumetric sequences 
into neuro-oncology imaging protocols would allow these 
measurements to be more easily made, if so desired. Manual 
delineation of tumour volumes is time consuming and can be 
prone to inter- and intraobserver error but software is now 
readily available which allows automated volume measure-
ment and has been shown to be more reliable than manual 
delineation.15
Figure 1. Post-contrast T1 weighted imaging of a patient with a recurrent left sphenoid meningioma. (a) and (b) Axial and cor-
onal reformats from a volumetric post-contrast T1 acquisition demonstrating conventional maximum trans-axial and coronal 
two-dimensional measurements from December 2018 with (c) demonstrating the semi-automated volumetric measure of the 
meningioma recurrence. (d–f) show corresponding images to (a–c) acquired 2 months later in February 2019 demonstrating no 
measurable change on conventional two-dimensional measurements but an approximately 8% increase in volume when quantita-
tive volumes are obtained increasing from 4.8 to 5.2 cm2.
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Practically, volumetric acquisitions typically take 7–8 min to 
perform per sequence and can be reformatted into any plane 
thus negating the need to acquire two different non-contiguous 
slice sequences (typically taking 4–5 min per acquisition). This 
is a more time-efficient method and the ability to reformat 
in any plane removes the ambiguity over whether contrast 
enhancement is genuine or a vascular entity (Figure  2). 
Consensus papers on recommendations for standardized 
protocols for clinical trials for glioma1 and neurofibroma-
tosis16 provide excellent guidance on which post-contrast T1 
protocols to use for volumetric imaging and these would be 
applicable to metastases and meningioma as well. The authors 
of these papers acknowledge that alternative and potentially 
improved volumetric sequences compared to the recommen-
dations are available, but at the time of publication, these 
sequences were not as widely available as they are today.
PerCeiveD DiSaDvantageS
Some radiologists and reporting radiographers may have 
concerns that the production of more imaging slices will both 
increase the error rate and take longer to review. There is no 
published evidence to support this. In fact, an early study 
of volumetric imaging demonstrated an increase in lesion 
conspicuity.17 Whilst we acknowledge that radiological review 
and interpretation of volumetric three-dimensional imaging 
may be more time consuming, this is unlikely to equate to a 
directly correlated increment in time in relation to the number 
of image slices, since volumetric image interpretation is 
processed by the radiologist in a different manner to two-di-
mensional image interpretation.18
Whilst manual segmentation and quantification of tumour 
volumes is time consuming and can demonstrate consider-
able inter- and intraobserver variability, validated software is 
readily available which provides automated and semi-automated 
methods of tumour volumetric assessment that is reliable and 
robust.15
ConClUSion
Volumetric imaging can increase efficiency in scan duration, 
aid diagnostic certainty removing ambiguity over genuine 
lesions and artefacts, and future proofs studies for more 
formal volumetric quantification when needed. Although, 
manual quantification of tumour volume is time consuming 
and can be error prone, this is not essential in the routine clin-
ical reporting of neuro-oncology scans. If formal volumetric 
quantification is desired, validated, reliable and robust soft-
ware is readily available which can perform this rapidly and 
accurately.
Overall, the benefits of performing volumetric imaging as part of 
the standard radiological assessment in clinical neuro-oncology 
seem to outweigh any perceived disadvantages.
Figure 2. (a) Axial T1 MPRAGE showing a left frontal cerebral metastasis from renal cell carcinoma (open white arrow). (b) The solid 
white arrow identifies an indeterminate focus of enhancement in the left occipital lobe, there is uncertainty on this axial imaging 
whether this reflects a separate small metastasis. (c–e) Standard axial, coronal and sagittal reformats of 3D imaging respectively 
shows enhancement (solid white arrow) is linear on the coronal reformat and, in fact, represents a vessel rather than a second 
metastatic deposit. 3D, three-dimensional.
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